medical breakthroughs




CAMBRIDGE, Mass. & STOCKHOLM–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of ALPROLIX® (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process.

CAMBRIDGE, Mass. & STOCKHOLM–Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has accepted…


Get Some Sleep Relief for Sleep Apnea

KANATA, Ontario, June 24, 2015 /PRNewswire/ — BRAEBON Medical Corporation announces today that the DentiTrac® oral appliance compliance system has passed a substantial regulatory hurdle and…





Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.